성장을 멈추지 마세요

체험은 만족하셨나요?

현재 45,775명이 마이메르시로 공부 중이에요

지식 자료를 소장하고 멋진 의료인으로 성장하세요

학습 자료 둘러보기 →
Medications for Diabetes Mellitus | 마이메르시 MyMerci
제안하기

뭔가 하고 싶은 말이 있는거야?

0 / 2000
컨텐츠 수정하기

컨텐츠 내용을 수정할 수 있습니다

수정하기
닫기

Medications for Diabetes Mellitus

NCLEX Review Guide: Diabetes Medications

Oral Antidiabetic Agents

Biguanides (Metformin)

  • Metformin decreases hepatic glucose production and increases peripheral glucose uptake and utilization. It is considered first-line therapy for type 2 diabetes due to its efficacy, safety profile, and potential weight loss benefits.
  • Administered with meals to minimize gastrointestinal side effects and typically started at low doses with gradual titration upward.

Key Points

  • Contraindicated in renal impairment (eGFR <30 mL/min) and should be held before procedures using iodinated contrast media.
  • Common side effects include diarrhea, nausea, abdominal discomfort, and metallic taste.
  • Rare but serious side effect: lactic acidosis (monitor for hyperventilation, abdominal pain, and malaise).

Sulfonylureas

  • Sulfonylureas (glipizide, glyburide, glimepiride) stimulate insulin secretion from pancreatic beta cells, requiring some residual beta cell function to be effective.
  • Second-generation agents (glipizide, glyburide, glimepiride) are more potent and have fewer drug interactions than first-generation agents.

Key Points

  • Major adverse effect is hypoglycemia, especially in elderly patients or those with impaired renal function.
  • Weight gain is a common side effect due to increased insulin levels.
  • Glyburide has the highest risk of hypoglycemia; glipizide and glimepiride have lower risks.

DPP-4 Inhibitors

  • DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) prevent the breakdown of incretin hormones, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner.
  • These medications are weight-neutral and have a low risk of hypoglycemia when used as monotherapy.

Key Points

  • Dose adjustment required for renal impairment for most DPP-4 inhibitors (except linagliptin).
  • Side effects include upper respiratory infections, headache, and potential joint pain.
  • Saxagliptin has been associated with increased risk of heart failure hospitalization in high-risk patients.

SGLT-2 Inhibitors

  • SGLT-2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin) block glucose reabsorption in the proximal tubule of the kidney, promoting urinary glucose excretion and lowering blood glucose independently of insulin.
  • These medications offer cardiovascular and renal benefits beyond glycemic control, particularly empagliflozin and canagliflozin, which have demonstrated reduced cardiovascular events in clinical trials.

Key Points

  • Risk of euglycemic diabetic ketoacidosis – must be discontinued before surgery or during acute illness.
  • Common side effects include genital mycotic infections and urinary tract infections due to glucosuria.
  • May cause volume depletion and hypotension; monitor elderly patients and those on diuretics carefully.
  • Canagliflozin has been associated with increased risk of lower limb amputations and bone fractures.

Thiazolidinediones (TZDs)

  • TZDs (pioglitazone, rosiglitazone) improve insulin sensitivity in peripheral tissues by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), primarily improving peripheral glucose uptake.
  • These medications have a slow onset of action, with maximal effects seen after 6-12 weeks of therapy.

Key Points

  • Contraindicated in heart failure (NYHA Class III-IV) due to fluid retention and edema.
  • Associated with weight gain, edema, and increased risk of fractures, particularly in women.
  • Requires liver function monitoring; discontinue if ALT >2.5-3 times upper limit of normal.

Injectable Antidiabetic Agents

Insulin Therapy

  • Insulin is the primary treatment for type 1 diabetes and may be necessary for type 2 diabetes when oral agents fail to achieve glycemic targets or during periods of acute illness, surgery, or pregnancy.
  • Insulin regimens are individualized based on patient factors, including lifestyle, glycemic targets, and hypoglycemia risk.

Insulin Types Memory Aid: "RAPID to LONG"

  • Rapid-acting: Lispro, Aspart, Glulisine (onset: 5-15 min, peak: 1-2 hrs, duration: 3-5 hrs)
  • Active short: Regular (onset: 30-60 min, peak: 2-4 hrs, duration: 6-8 hrs)
  • Protracted intermediate: NPH (onset: 1-2 hrs, peak: 4-12 hrs, duration: 12-18 hrs)
  • Intermediate duration: NPH (same as above)
  • Daily long-acting: Glargine, Detemir (onset: 1-2 hrs, peak: minimal, duration: 20-24 hrs)
  • Long-lasting: Degludec (onset: 1-2 hrs, peak: minimal, duration: >24 hrs)

Key Points

  • Major adverse effect is hypoglycemia; educate patients on recognition and management.
  • Basal-bolus regimens most closely mimic physiologic insulin secretion, with basal insulin (long-acting) plus bolus insulin (rapid-acting) before meals.
  • Insulin concentration is typically 100 units/mL (U-100); higher concentrations (U-200, U-300, U-500) are available for insulin-resistant patients.

Clinical Scenario: Insulin Administration

A 45-year-old patient with type 1 diabetes is admitted with hyperglycemia (blood glucose 420 mg/dL) and requires subcutaneous insulin. The order is for 10 units of regular insulin and 20 units of NPH insulin.

  1. Verify the order and patient using two identifiers
  2. Draw up regular insulin first (clear solution) into the syringe
  3. Without changing the needle, draw up NPH insulin (cloudy solution) second
  4. Administer at a 90-degree angle into the abdomen, rotating injection sites
  5. Document administration and monitor for hypoglycemia

GLP-1 Receptor Agonists

  • GLP-1 receptor agonists (exenatide, liraglutide, dulaglutide, semaglutide, lixisenatide) mimic the action of endogenous GLP-1, increasing glucose-dependent insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and promoting satiety.
  • These agents are available in short-acting (exenatide, lixisenatide) and long-acting (liraglutide, dulaglutide, semaglutide, exenatide extended-release) formulations with varying administration schedules from twice daily to once weekly.

Key Points

  • Associated with significant weight loss (3-5 kg on average) and low risk of hypoglycemia when used as monotherapy.
  • Liraglutide, dulaglutide, and semaglutide have demonstrated cardiovascular benefits in clinical trials.
  • Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
  • Common side effects include nausea, vomiting, and diarrhea, which typically improve with continued use.

Amylin Analogs

  • Pramlintide is a synthetic analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells, which slows gastric emptying, reduces postprandial glucagon secretion, and promotes satiety.
  • Used as adjunctive therapy with mealtime insulin in both type 1 and type 2 diabetes to reduce postprandial glucose excursions.

Key Points

  • Must be administered as a separate injection from insulin (cannot be mixed in the same syringe).
  • Associated with weight loss and reduction in insulin requirements.
  • Increased risk of hypoglycemia; insulin doses often need to be reduced when initiating pramlintide.
  • Common side effects include nausea, vomiting, anorexia, and headache.

Commonly Confused Medications

Sulfonylureas vs. Meglitinides

Feature Sulfonylureas Meglitinides
Examples Glipizide, Glyburide, Glimepiride Repaglinide, Nateglinide
Mechanism Close ATP-sensitive K+ channels in beta cells Close ATP-sensitive K+ channels in beta cells (same target, different binding site)
Duration Longer-acting (once or twice daily) Shorter-acting (taken before meals)
Hypoglycemia risk Higher Lower (due to shorter duration)
Meal timing Less dependent on meal timing Must be taken with meals; can skip if meal is skipped
Renal impairment Most contraindicated or require dose adjustment Repaglinide can be used with caution

DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Feature DPP-4 Inhibitors GLP-1 Receptor Agonists
Examples Sitagliptin, Saxagliptin, Linagliptin, Alogliptin Exenatide, Liraglutide, Dulaglutide, Semaglutide
Administration Oral tablets Injectable (subcutaneous)
Effect on GLP-1 Prevents breakdown of endogenous GLP-1 Directly activates GLP-1 receptors
A1C reduction Modest (0.5-0.8%) Greater (1.0-1.8%)
Effect on weight Weight neutral Weight loss (3-5 kg)
GI side effects Minimal Common (nausea, vomiting, diarrhea)
CV benefit Neutral (potential concern with saxagliptin) Proven benefits with liraglutide, semaglutide, dulaglutide

Basal Insulin vs. Bolus Insulin

Feature Basal Insulin Bolus Insulin
Examples Glargine, Detemir, Degludec, NPH Lispro, Aspart, Glulisine, Regular
Purpose Controls blood glucose between meals and overnight Controls blood glucose after meals
Timing Usually once or twice daily at same time Before meals (rapid-acting) or 30 min before meals (regular)
Peak action Minimal peak (glargine, detemir, degludec) or broad peak (NPH) Pronounced peak 1-2 hours (rapid) or 2-4 hours (regular)
Duration 12-24+ hours 3-8 hours
Dose adjustment Based on fasting glucose levels Based on carbohydrate intake and pre-meal glucose

Study Tips and Memory Aids

Key Mechanisms of Action

Diabetes Medication Mechanisms Memory Aid: "SIMBA"

  • Stimulate insulin secretion: Sulfonylureas, Meglitinides
  • Increase insulin sensitivity: Thiazolidinediones
  • Metformin: Decreases hepatic glucose production
  • Block glucose reabsorption: SGLT-2 inhibitors
  • Augment incretin effect: DPP-4 inhibitors, GLP-1 receptor agonists

Oral Diabetes Medications Side Effects: "WHEN SUGAR FALLS"

  • Weight gain: Sulfonylureas, TZDs
  • Hypoglycemia: Sulfonylureas, Meglitinides
  • Edema: TZDs
  • Nausea/GI effects: Metformin, GLP-1 RAs
  • Sweet urine/UTIs: SGLT-2 inhibitors
  • Urticaria/allergic reactions: Any medication
  • Gastrointestinal upset: Metformin, GLP-1 RAs
  • Acidosis (lactic): Metformin
  • Renal dosing required: Most oral agents
  • Fractures: TZDs, Canagliflozin
  • Amputation risk: Canagliflozin
  • Liver monitoring: TZDs
  • Low blood pressure: SGLT-2 inhibitors
  • Skin reactions: Any medication

Insulin Administration Techniques

Insulin Injection Sites Memory Aid: "AALT"

  • Abdomen: Fastest absorption, preferred site for most injections
  • Arms (upper outer): Moderate absorption
  • Legs (thighs): Slower absorption
  • Thighs (buttocks): Slowest absorption

Remember: Exercise increases absorption rate at the site closest to the exercising muscles.

Patient Education for Insulin Storage

  • Unopened insulin vials and pens should be stored in the refrigerator (36-46°F, 2-8°C).
  • In-use insulin can be kept at room temperature (<86°F, 30°C) for up to 28 days (check specific product guidelines).
  • Never freeze insulin or expose to direct heat or sunlight.
  • Inspect insulin before use – clear insulins should remain clear, NPH should be uniformly cloudy after mixing.

Common Pitfalls in Diabetes Medication Management

Common Pitfalls

  • Failure to adjust insulin during illness or changes in activity: Illness typically increases insulin requirements, while increased exercise may decrease requirements.
  • Not recognizing that euglycemic DKA can occur with SGLT-2 inhibitors, even when blood glucose levels are not significantly elevated.
  • Overlooking the need to reduce insulin doses when starting a GLP-1 receptor agonist, which can lead to hypoglycemia.
  • Continuing metformin before procedures with contrast dye, increasing the risk of lactic acidosis.
  • Not adjusting medication doses in patients with declining renal function, which can lead to drug accumulation and adverse effects.

Self-Assessment

Quick Check: Test Your Knowledge

  1. Which medication increases the risk of lactic acidosis and should be held before contrast studies? Metformin
  2. Which class of diabetes medications promotes weight loss through urinary glucose excretion? SGLT-2 inhibitors
  3. Which insulin type has the most rapid onset of action? Rapid-acting analogs (lispro, aspart, glulisine)
  4. Which injectable diabetes medication requires separate administration from insulin? Pramlintide
  5. Which oral diabetes medication class is contraindicated in heart failure? Thiazolidinediones (TZDs)

Knowledge Checklist








Remember: Understanding diabetes medications is crucial for safe patient care. Focus on mechanism of action, timing, side effects, and patient education needs. You've got this!

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.